Machine Learning and Integrative Analysis of Biomedical Big Data.

Recent developments in high-throughput technologies have accelerated the accumulation of massive amounts of omics data from multiple sources: genome, epigenome, transcriptome, proteome, metabolome, etc. Traditionally, data from each source (e.g., genome) is analyzed in isolation using statistical and machine learning (ML) methods. Integrative analysis of multi-omics and clinical data is key to new biomedical discoveries and advancements in precision medicine. However, data integration poses new computational challenges as well as exacerbates the ones associated with single-omics studies. Specialized computational approaches are required to effectively and efficiently perform integrative analysis of biomedical data acquired from diverse modalities. In this review, we discuss state-of-the-art ML-based approaches for tackling five specific computational challenges associated with integrative analysis: curse of dimensionality, data heterogeneity, missing data, class imbalance and scalability issues

A data mining framework based on boundary-points for gene selection from DNA-microarrays: Pancreatic Ductal Adenocarcinoma as a case study

[EN] Gene selection (or feature selection) from DNA-microarray data can be focused on different techniques, which generally involve statistical tests, data mining and machine learning. In recent years there has been an increasing interest in using hybrid-technique sets to face the problem of meaningful gene selection; nevertheless, this issue remains a challenge. In an effort to address the situation, this paper proposes a novel hybrid framework based on data mining techniques and tuned to select gene subsets, which are meaningfully related to the target disease conducted in DNA-microarray experiments. For this purpose, the framework above deals with approaches such as statistical significance tests, cluster analysis, evolutionary computation, visual analytics and boundary points. The latter is the core technique of our proposal, allowing the framework to define two methods of gene selection. Another novelty of this work is the inclusion of the age of patients as an additional factor in our analysis, which can leading to gaining more insight into the disease. In fact, the results reached in this research have been very promising and have shown their biological validity. Hence, our proposal has resulted in a methodology that can be followed in the gene selection process from DNA-microarray data